TY - JOUR
T1 - Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study
AU - Hoefer, Imo E.
AU - Sels, Jan-Willem
AU - Jukema, J. Wouter
AU - Bergheanu, Sandrin
AU - Biessen, Erik
AU - McClellan, Elizabeth
AU - Daemen, Mat
AU - Doevendans, Pieter
AU - de Groot, Philip
AU - Hillaert, Marieke
AU - Horsman, Sebastiaan
AU - Ilhan, Mustafa
AU - Kuiper, Johan
AU - Pijls, Nico
AU - Redekop, Ken
AU - van der Spek, Peter
AU - Stubbs, Andrew
AU - van de Veer, Eric
AU - Waltenberger, Johannes
AU - van Zonneveld, Anton-Jan
AU - Pasterkamp, Gerard
PY - 2013/11
Y1 - 2013/11
N2 - Biomarkers for primary or secondary risk prediction of cardiovascular disease (CVD) are urgently needed to improve individual treatment and clinical trial design. The vast majority of biomarker discovery studies has concentrated on plasma/serum as an easily accessible source. Although numerous markers have been identified, their added predictive value on top of traditional risk factors has been limited, as the biological specimen does not specifically reflect expression profiles related with CVD progression and because the signal is often diluted by marker release from other organs. In contrast to serum markers, circulating cells serve as indicators of the actual disease state due to their active role in the pathogenesis of CVD and are responsible for the majority of secreted biomarkers. Therefore, the CIRCULATING CELLS study was initiated, focusing on the cellular effectors of atherosclerosis in the circulation. In total, 714 patients with coronary artery disease (CAD) symptoms were included. Blood cell fractions (monocytes, T-lymphocytes, platelets, granulocytes, PBMC) of all individual patients were isolated and stored for analysis. Concomitantly, extensive flow cytometric characterization of these populations was performed. From each patient, a detailed clinical profile together with extensive questionnaires about medical history and life style was obtained. Various high-throughput -omics approaches (protein, mRNA, miRNA) are currently being undertaken. Data will be integrated with advanced bioinformatics for discovery and validation of secondary risk markers for adverse events. Overall, the CIRCULATING CELLS study grants the interesting possibility that it will both identify novel biomarkers and provide useful insights into the pathophysiology of CAD in patients.
AB - Biomarkers for primary or secondary risk prediction of cardiovascular disease (CVD) are urgently needed to improve individual treatment and clinical trial design. The vast majority of biomarker discovery studies has concentrated on plasma/serum as an easily accessible source. Although numerous markers have been identified, their added predictive value on top of traditional risk factors has been limited, as the biological specimen does not specifically reflect expression profiles related with CVD progression and because the signal is often diluted by marker release from other organs. In contrast to serum markers, circulating cells serve as indicators of the actual disease state due to their active role in the pathogenesis of CVD and are responsible for the majority of secreted biomarkers. Therefore, the CIRCULATING CELLS study was initiated, focusing on the cellular effectors of atherosclerosis in the circulation. In total, 714 patients with coronary artery disease (CAD) symptoms were included. Blood cell fractions (monocytes, T-lymphocytes, platelets, granulocytes, PBMC) of all individual patients were isolated and stored for analysis. Concomitantly, extensive flow cytometric characterization of these populations was performed. From each patient, a detailed clinical profile together with extensive questionnaires about medical history and life style was obtained. Various high-throughput -omics approaches (protein, mRNA, miRNA) are currently being undertaken. Data will be integrated with advanced bioinformatics for discovery and validation of secondary risk markers for adverse events. Overall, the CIRCULATING CELLS study grants the interesting possibility that it will both identify novel biomarkers and provide useful insights into the pathophysiology of CAD in patients.
KW - Study design
KW - Biomarker
KW - Risk prediction
KW - Cardiovascular disease
U2 - 10.1007/s00392-013-0607-9
DO - 10.1007/s00392-013-0607-9
M3 - Article
C2 - 23975238
SN - 1861-0684
VL - 102
SP - 847
EP - 856
JO - Clinical research in cardiology
JF - Clinical research in cardiology
IS - 11
ER -